Biomarkers Associated with Clinical Outcomes of CAR-T Cell Therapies for Relapse/Refractory Multiple Myeloma

• Biomarker data associated with clinical efficacy and safety from CARTITUDE studies with cilta-cel
• Correlative analysis and mechanistic data to support the use of cilta-cel in earlier lines of therapy for relapse/refractory multiple myeloma patients

Speakers:

Vicki Plaks

Senior Director, Scientific, Head of Cell Therapy, Oncology Translational Research

Johnson & Johnson